Editor's Corner

Coming off of another successful gathering of BIO, it was interesting to see the heightened -- delirious might be a better word -- interest in biotech by economic development groups from around the world. Biotech is the hottest business in the development world and they pulled out all the stops to woo companies at the gathering in Philadelphia. The host city even pulled off a top ranking in a list of bioclusters put together by the Milken Institute. Their numbers were notoriously padded, of course, in this case by pooling general healthcare employment with biotech. But it's a sign of the luster surrounding biotech that development officials are willing to try so hard to please the industry. Can Chicago top that act next year? We'll see next April. - John Carroll

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.